Abbott Park, Illinois (ots/PRNewswire) - - Two publicly traded companies will offer shareholders distinct opportunities given unique investment identities, business profiles and attributes - Builds on a decade of strategic and operational advancements Today Abbott announced that it plans to separate into two ...
Abbott Park, Illinois (ots/PRNewswire) - Abbott announced today that it plans to develop two new formulations of its HIV medicines, Kaletra (lopinavir/ritonavir) and Norvir (ritonavir), to offer new formulation options for people living with HIV-1. The company is currently investigating a new powder formulation of ...
ABBOTT PARK, Illinois and REDWOOD CITY, California, March 9, 2010 (ots/PRNewswire) -- Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline. Abbott will acquire Facet for US$27 per share in cash for a net transaction value of approximately US$450 ...
Abbott Park, Illinois, March 2, 2010 (ots/PRNewswire) - Imagine delaying a life-saving surgery or being afraid to receive or donate blood for fear of contracting HIV (http://www.who.int/hiv/en/). It seems unbelievable today, but twenty-five years ago, this was the reality as the world struggled to keep the deadly virus out of the blood supply. (Photo: ...
Abbott Park, Illinois, February 16, 2010 (ots/PRNewswire) - Abbott today announced that it has completed its EUR 4.5 billion (US$6.2 billion) acquisition of Belgium-based Solvay Pharmaceuticals, providing Abbott with a large and complementary portfolio of pharmaceutical products and expanding Abbott's presence in key global emerging markets. Based on the timing of the close, Abbott expects the acquisition to add ...
Abbott Park, Illinois (ots/PRNewswire) - Today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) voted to recommend the suspension of marketing authorizations for all anti-obesity medicines containing sibutramine. Abbott will comply with the CHMP recommendation and suspend the marketing of Abbott medicines containing ...
Abbott Park, Illinois (ots/PRNewswire) - A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the assessment of epithelial ovarian cancer, the most lethal form of gynecological cancer. This important immunoassay, which will ...
Des Plaines, Illinois (ots/PRNewswire) - Abbott announced today it has received CE Marking (Conformite Europeene) in the European Union for a new molecular diagnostic test, Abbott RealTime mS9 Colorectal Cancer, a non-invasive DNA assay that detects the methylated form of Septin 9, a gene linked to colorectal cancer, in blood specimens. The product is not available for sale in the United States. The RealTime mS9 ...
Orlando, Florida, November 16 (ots/PRNewswire) - - New ABSORB EXTEND Trial to Study Performance of Revolutionary Bioabsorbable Device in Approximately 1,000 Patients Abbott (NYSE: ABT) today announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating ...
Abbott Park, Illinois (ots/PRNewswire) - - Diversifies Abbott's pharmaceutical products, expanding international growth platform - Supports long-term strategy to bolster presence in key global emerging markets - Adds substantial R&D spending capacity to accelerate promising pipeline programs - Establishes Abbott's presence in the growing global vaccines market - Provides accretion of approximately ...
San Francisco (ots/PRNewswire) - Abbott (NYSE: ABT) today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the first prospective natural history study to evaluate the role of vulnerable ...
San Francisco (ots/PRNewswire) - - Independent Study of 1,800 Patients Affirms Outstanding Performance of XIENCE V vs. TAXUS Liberte Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's (NYSE: ABT) market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System ...
San Francisco (ots/PRNewswire) - At One Year, XIENCE V Demonstrates: - Statistical Superiority on Primary Endpoint of Target Lesion Failure, with a 38 Percent Reduction Compared to TAXUS - 74 Percent Reduction in Stent Thrombosis (Blood Clots) Compared to TAXUS - Low Event Rates across Multiple ...
San Francisco (ots/PRNewswire) - - Market-Leading XIENCE V Demonstrates Single-Digit Rate of Major Adverse Cardiac Events (MACE) at Three Years and a 43 Percent Reduction vs. TAXUS - No Additional Stent Thrombosis between Two and Three Years, and Impressive Low Rate of Very Late Stent Thrombosis for ...
Barcelona, Spain (ots/PRNewswire) - - New Cobalt Chromium Stent Offers Enhanced Deliverability with a Broad Matrix of Sizes - Built Upon the Proven Track Record of Superior Clinical Outcomes of Abbott's Market-Leading XIENCE V(R) Drug Eluting Stent Abbott (NYSE: ABT) today announced at the European Society of Cardiology Congress the widespread ...
Abbott Park, Illinois (ots/PRNewswire) - - Broad Size Matrix of XIENCE PRIME to be Launched in Europe in the Third Quarter Abbott announced today that it has received CE Mark (Conformite Europeenne) for its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of ...
Abbott Park, Illinois (ots/PRNewswire) - - Abbott Only U.S.-based Fortune 100 Health Care Manufacturer to Be Listed on Both North America and World Indexes Abbott (NYSE: ABT), the global health care company, announced today that it was recognized on the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index for the fourth ...
Mexico City (ots/PRNewswire) - - Pivotal Study of Norvir Tablet Bioavailability Will Form the Basis of Request for Priority Regulatory Review Abbott (NYSE: ABT) presented pivotal data at the XVII International AIDS Conference (AIDS 2008) in Mexico City today showing that its investigational Norvir(R) ...
Mexico City (ots/PRNewswire) - - HIV-Infected Women and Non-Whites New to Antiretroviral Therapy Respond Similarly to Men and Whites Initial treatment regimens containing once-daily or twice-daily dosing of Abbott's (NYSE: ABT) protease inhibitor Kaletra(R) (lopinavir/ritonavir) tablet provided similar ...
Dar Es Salaam, Tanzania (ots/PRNewswire) - - Partnership Will Modernize All Regional Hospital Laboratories to Improve Access to Care Across the Country At a ceremony today, the Ministry of Health and Social Welfare, United Republic of Tanzania, and Abbott Fund commemorated the latest step in a nationwide ...
Abbott Park, Illinois (ots/PRNewswire) - - XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for Treatment of Coronary Artery Disease Abbott today announced that the U.S. Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE ...
Johannesburg, South Africa (ots/PRNewswire) - - More than 5 Million South Africans Living with HIV Gain Access to First and Only Co-formulated, Non-refrigerated Protease Inhibitor Abbott (NYSE: ABT) today announced that the new tablet formulation of its protease inhibitor Aluvia(R) (lopinavir/ritonavir), for the treatment of HIV-1, is now available to ...
Abbott Park, Illinois (ots/PRNewswire) - - New Device Designed to Provide Fast, Safe and Secure Vessel Closure Following Catheterization Procedures Abbott today announced the launch of the StarClose(R) SE Vascular Closure System, a next-generation vessel closure device engineered to enable fast, safe and secure closure of the femoral artery access site ...
Barcelona, Spain (ots/PRNewswire) - - Data from SPIRIT II and III Clinical Trials Also Show Improvement in Vessel Renarrowing with XIENCE V Compared to TAXUS in Patients with Small Vessels Data presented today from an independent pooled subset analysis of Abbott's SPIRIT II and SPIRIT III clinical ...
Barcelona, Spain (ots/PRNewswire) - - Patients Treated with XIENCE V in SPIRIT III Trial Experience Better Long-Term Clinical Outcomes, Lower Rates of Stent Thrombosis than Patients Treated with TAXUS Long-term data presented for the first time today from the SPIRIT III trial, Abbott's U.S. pivotal trial ...
Abbott Park, Illinois (ots/PRNewswire) - - Lopinavir/ritonavir Tablet is the First and Only Co-Formulated Protease Inhibitor Tablet Approved for Use in Children with HIV Abbott announced today that it has received marketing authorization from the European Commission for the new, lower-strength tablet ...
Abbott Park, Illinois (ots/PRNewswire) - - Improved Medical Benefit Rating Granted for XIENCE V from French Health Authority Abbott (NYSE: ABT) today announced that it has received reimbursement approval in France for its XIENCE(TM) V Everolimus Eluting Coronary Stent System, the first drug eluting stent to demonstrate clinical superiority over another drug ...
Abbott Park, Illinois (ots/PRNewswire) - - Lopinavir/ritonavir tablet is the first and only co-formulated protease inhibitor tablet approved for use in children with HIV Abbott (NYSE: ABT) announced today that the European Committee for Medicinal Products for Human Use (CHMP), the scientific committee ...
Abbott Park, Illinois and South San Francisco, California (ots/PRNewswire) - Abbott (NYSE: ABT) and Genentech, Inc. (NYSE: DNA) have formed a collaboration for the global research, development and commercialization of two of Abbott's investigational anti-cancer compounds. The companies will work together on ...
Abbott Park, Illinois (ots/PRNewswire) - - First-of-its-Kind Study Designed to Learn More About Cardiovascular Disease in Women Abbott today announced plans to initiate the world's first drug-eluting stent clinical trial solely in women. The SPIRIT WOMEN trial will aim to increase understanding of how ...